NCT00748501 - Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

SB-509

Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.

Trial Locations (6)

Johns Hopkins University, Baltimore

The University of Kansas Medical Center (KU), Kansas City

Nerve and Muscle Center of Texas, Houston

Coordinated Clinical Research, La Jolla

University of California, Irvine; MDA ALS and Neuromuscular Center,, Orange

California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center, San Francisco